Famotidine onset of action

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Famotidine Onset of Action in Healthy Individuals and Patients

Onset of Action After Oral Administration

In healthy individuals, famotidine begins to reduce gastric acid secretion within one hour after oral administration, with the maximum effect typically occurring between one and three hours after taking the medication 2Chremos19876. This rapid onset makes famotidine effective for conditions requiring quick acid suppression.

Onset of Action After Intravenous Administration

When administered intravenously, famotidine also shows a prompt onset of action. In healthy controls, the onset of action was observed at approximately 36 to 54 minutes, depending on the time of administration . This is generally faster than oral administration due to direct entry into the bloodstream.

Onset of Action in Special Populations

In patients undergoing hemodialysis, the onset of famotidine’s action is delayed compared to healthy individuals. For these patients, the onset occurred around 90 to 99 minutes after intravenous administration, which is significantly slower than in healthy controls . The time of day did not affect the onset in hemodialysis patients, but in healthy individuals, evening administration slightly delayed the onset compared to afternoon dosing .

Comparison with Other H2-Receptor Antagonists

Studies comparing famotidine with other H2-receptor antagonists, such as ranitidine and cimetidine, found that all three drugs have a similar time course for onset of action, with maximal effects seen at three to four hours after oral ingestion Vinayek1986Howard1985. However, famotidine has a longer duration of action and greater potency than the other agents Vinayek1986Howard1985.

Conclusion

Famotidine typically begins to work within one hour after oral administration and even sooner after intravenous administration in healthy individuals. The onset may be delayed in patients with impaired kidney function, such as those on hemodialysis. Compared to other H2-receptor antagonists, famotidine’s onset of action is similar, but it offers a longer duration and higher potency.

Sources and full results

Most relevant research papers on this topic

Intragastric long-term pH-metry in hemodialysis patients. A study with famotidine.

Famotidine has a retarded and prolonged action in hemodialysis patients, with no effect on the time of administration, unlike in normal subjects, where evening administration delays the onset and prolongs the duration of famotidine action.

1991·

4citations

·U. Gladziwa et al.

Clinical nephrology

Famotidine Tablets USP

Famotidine effectively inhibits gastric secretion in normal volunteers and hypersecretors, with a maximum effect occurring within one to three hours after oral administration.

2018·

0citations

Famotidine in the therapy of gastric hypersecretory states.

Famotidine is a safe and highly effective long-term treatment for gastric hypersecretory states, with a 30% longer duration of action and nine times more potency than ranitidine and 32 times more potency than cimetidine.

Observational Study

1986·

46citations

·R. Vinayek et al.

The American journal of medicine·

DOI

Clinical pharmacology of famotidine: a summary.

Famotidine effectively inhibits gastric acid secretion, with a 40 mg dose providing the highest inhibitory effect and the longest duration of action, and does not affect other functions in the body.

1987·

29citations

·A. Chremos

Journal of clinical gastroenterology·

DOI

Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.

Famotidine is a potent, long-acting histamine H2-receptor antagonist that is nine times more potent than ranitidine and 32 times more potent than cimetidine, and is safe and effective for long-term therapy of Zollinger-Ellison syndrome.

Non-RCTHighly Cited

1985·

168citations

·J. Howard et al.

Gastroenterology·

DOI

FAMOTIDINE- famotidine for suspens ion Lupin Pharmaceuticals ,Inc. ---------- Famotidine for Oral Suspens ion, USP DESCRIPTION The active ingredient in Famotidine for Oral Suspension is a histamine H -receptor antagonist. Famotidine is N-(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4- thiazolyl]

Famotidine for Oral Suspension is a histamine H-receptor antagonist that inhibits gastric secretion, with a maximum effect occurring within one to three hours after oral administration.

2017·

0citations

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms

Famotidine may relieve COVID-19 symptoms by targeting histamine receptor H2, which is involved in dysfunctional mast cell activation and histamine release.

Highly Cited

2020·

102citations

·R. Malone et al.

Frontiers in Pharmacology·

DOI

Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease

Famotidine can enhance the anti-parkinsonian effects of low dose levodopa and extend its duration without producing disabling dyskinesia, while also reducing peak-dose levodopa-induced chorea and improving on-time quality in Parkinson's disease patients.

Non-RCTAnimal Study

2010·

44citations

·T. Johnston et al.

Movement Disorders·

DOI

Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm

Famotidine activates the vagus nerve inflammatory reflex to reduce inflammation in severe COVID-19 patients, improving survival and demonstrating a central nervous system mechanism of action.

Non-RCTAnimal StudyRigorous Journal

2022·

23citations

·Huan Yang et al.

Molecular Medicine·

DOI

Famotidine increases cellular phospho-tyrosine levels

Famotidine can increase the anti-viral state of non-infected cells, potentially increasing viral resistance.

In Vitro Study

2024·

1citation

·Imanol Zubiete-Franco et al.

Biochemical and biophysical research communications·

DOI

Try another search

metformin and weight loss in women with pcos

side effects of medication

identification of unknown pills

bone density

collagen peptide supplementation

lisinopril mechanism of action